Abivax Shares Drop 5% in Session Despite a Twentyfold Increase in Price Over the Year
The stock of French biotech company Abivax significantly dropped this Monday, April 13, falling to 102.40 euros after closing at 107.90 euros on Friday. This decline of 5.1% occurs in a weakened Paris market environment, with the CAC 40 losing more than 1% during the session. The company, whose stock price has increased more than twentyfold in a year, is experiencing a sharp correction despite a generally favorable recent dynamic.
Abivax Stock Experiences Greater Decline Than Overall Paris Market
Abivax stock has seen a notably greater decline than the overall Paris market this Monday. The CAC 40 is down 1.01% during the session, while the SBF 120 shows similar declines. The pharmaceutical and biotech sector is not spared: Sanofi is down 1.46% and UCB loses 0.87%. Abivax's more pronounced drop is partly explained by a beta of 2.68, indicating a particularly high sensitivity to market movements. The stock's monthly volatility, measured at 56.24, confirms the extent of fluctuations it regularly undergoes.
This tense context is fueled by the announcement of an American naval blockade against Iran, initiated this April 13 following the failure of the Islamabad negotiations. Oil has surged above $100 a barrel, reviving fears of major disruptions on global markets. Although Abivax is not directly exposed to raw materials, the generalized risk aversion weighs mechanically on high-volatility stocks like biotechs.
Technical Analysis of Abivax Stock
Technically, Abivax's stock price remains above its 20-day and 50-day moving averages, located at 101.15 euros and 101.12 euros respectively, which now serve as a first point of support. The 200-day moving average, at 81.81 euros, remains far off, reflecting the long-term bullish trend supported by an annual performance of nearly 2000%. The RSI, at 60, indicates that the stock is neither in an overbought nor oversold zone, allowing room for movement in both directions.
The price is currently positioned midway between the Bollinger Bands, with the upper bound at 113.69 euros and the lower bound at 88.61 euros. This central positioning reflects the absence of extreme signals despite the day's decline. The nearest resistance threshold is at 109.60 euros, while the identified support is at 88.80 euros, close to the lower Bollinger Band. The next financial appointment is scheduled for June 1, 2026, with the publication of the first quarter results.
